Compass Therapeutics announced it granted 200,000 stock options to a new employee as part of its 2025 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.86 per share, matching the stock's closing price on October 13, 2026, with a 10-year term and vesting over four years. This inducement grant is outside the company's 2020 Stock Option Plan and aims to attract talent to support its oncology-focused biopharmaceutical development. Compass continues to advance its pipeline of antibody-based cancer therapies from its Boston headquarters.
Compass Therapeutics' inducement grants provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 15, 2026 03:02 WIB: Of 150 priced US health-sector stocks, 90 rose and 60 fell today. Notable movers include MMED at USD 16.71 with a 1-day change of -9.18% and a typical hold time of 6 days, ALMS at USD 6.08 down 7.39% with 100% buy order activity, and HRTX at USD 0.36 down 6.89% with a typical hold time of 36 days and 67% buy order activity.
Stephany Insurance LLC, a fourth-generation independent agency in Wexford, PA, is highlighted in a new 2026 guide for helping small businesses in Pittsburgh's North Hills identify and close insurance coverage gaps caused by rising premiums. The guide...
The Knowles-Rowland House, a $13.96 million redevelopment project by Bread of Life Inc., has opened in Midtown Houston, providing 31 permanent supportive housing units for individuals exiting chronic homelessness. The building, formerly a fire-damage...
ATLAS SP Partners, majority owned by Apollo funds, announced the pricing of $750 million senior notes due 2032 with a fixed 6.25% interest rate until November 2031, then switching to a floating rate based on SOFR plus a spread. The notes, issued by A...
Bending Spoons led market gainers with a 41.2% rise after Berkshire Hathaway increased its stake to 4% by investing an additional $330 million. Antelope Enterprise gained 36.4%, and NEXGEL rose 32.1% following a reverse stock split. Liquidia advanced...
The Law Offices of Frank R. Cruz is investigating Alignment Healthcare following a whistleblower lawsuit claiming the company misclassified $8-10 million in expenses to inflate its adjusted EBITDA and stock price. This alleged accounting manipulation...
